Catalent, Inc. (NYSE:CTLT) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. raised its holdings in Catalent, Inc. (NYSE:CTLT) by 0.1% in the third quarter, Holdings Channel reports. The fund owned 208,206 shares of the company’s stock after buying an additional 229 shares during the period. Principal Financial Group Inc.’s holdings in Catalent were worth $12,611,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of CTLT. Vanguard Group Inc. increased its holdings in shares of Catalent by 1.1% in the first quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock valued at $1,151,872,000 after purchasing an additional 218,682 shares during the last quarter. Millennium Management LLC grew its holdings in Catalent by 129.2% in the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after buying an additional 2,299,784 shares in the last quarter. Alpine Associates Management Inc. increased its stake in shares of Catalent by 3.8% in the 2nd quarter. Alpine Associates Management Inc. now owns 2,061,251 shares of the company’s stock worth $115,904,000 after acquiring an additional 75,700 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Catalent by 14.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,930,621 shares of the company’s stock worth $108,559,000 after acquiring an additional 250,999 shares during the period. Finally, Marshall Wace LLP boosted its position in shares of Catalent by 5.1% during the 2nd quarter. Marshall Wace LLP now owns 1,792,951 shares of the company’s stock valued at $100,818,000 after acquiring an additional 86,533 shares during the last quarter.

Catalent Stock Performance

NYSE:CTLT opened at $59.10 on Friday. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.20. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The company has a 50 day moving average price of $59.84 and a 200 day moving average price of $58.20. The stock has a market capitalization of $10.73 billion, a P/E ratio of -26.15, a PEG ratio of 2.35 and a beta of 1.16.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.10) earnings per share. Equities research analysts forecast that Catalent, Inc. will post 0.84 EPS for the current year.

Insider Buying and Selling at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 in the last three months. 0.31% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CTLT. StockNews.com raised shares of Catalent from a “sell” rating to a “hold” rating in a research note on Thursday. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.